Clinical Profile and a Comparative Study on the Effectiveness of Nintedanib and Corticosteroids in Interstitial Lung Disease at a Tertiary Care Teaching Centre
Author(s)
Pooja Lakshmi, RPh.
Pharmacy Practice, National College of Pharmacy, Kozhikode, India.
Pharmacy Practice, National College of Pharmacy, Kozhikode, India.
OBJECTIVES: To study the clinical profile and effectiveness of Nintedanib and corticosteroids in Interstitial Lung Disease (ILD).
METHODS: A prospective cross-sectional observational study was conducted on 58 patients who met the inclusion criteria, from December 2022 to June 2023.
RESULTS: Among the 58 patients, 52% were women, with a mean age of 59 years. Common symptoms included breathlessness and dry cough. Key risk factors were occupational exposure (12%), prior tuberculosis (12%), and COVID-19 infection (10.3%). Comorbidities included rheumatoid arthritis (14%) and diabetes mellitus (17%). High-resolution computed tomography (HRCT) findings commonly revealed honeycombing with traction bronchiectasis (9%) and ground-glass opacities with honeycombing (9%). The most frequent ILD diagnoses were idiopathic pulmonary fibrosis (IPF, 29.3%) and nonspecific interstitial pneumonia (NSIP, 25.8%). IPF was the most prevalent ILD and had a worse prognosis and higher mortality rate compared to NSIP. Patients on corticosteroid therapy demonstrated a better trend in forced vital capacity (FVC) and forced expiratory volume in one second (FEV₁) on spirometry than those on Nintedanib. The six-minute walk test (6MWT) indicated greater improvement in the Nintedanib group (11.6 meters). Therapy response varied with ILD subtype.
CONCLUSIONS: This study shows that Nintedanib is effective in fibrotic ILDs, while corticosteroids benefit inflammatory types. The findings highlight the complexity of ILD management and the need for further research to optimize treatment strategies. This work lays a foundation for evidence-based, personalized ILD care.
METHODS: A prospective cross-sectional observational study was conducted on 58 patients who met the inclusion criteria, from December 2022 to June 2023.
RESULTS: Among the 58 patients, 52% were women, with a mean age of 59 years. Common symptoms included breathlessness and dry cough. Key risk factors were occupational exposure (12%), prior tuberculosis (12%), and COVID-19 infection (10.3%). Comorbidities included rheumatoid arthritis (14%) and diabetes mellitus (17%). High-resolution computed tomography (HRCT) findings commonly revealed honeycombing with traction bronchiectasis (9%) and ground-glass opacities with honeycombing (9%). The most frequent ILD diagnoses were idiopathic pulmonary fibrosis (IPF, 29.3%) and nonspecific interstitial pneumonia (NSIP, 25.8%). IPF was the most prevalent ILD and had a worse prognosis and higher mortality rate compared to NSIP. Patients on corticosteroid therapy demonstrated a better trend in forced vital capacity (FVC) and forced expiratory volume in one second (FEV₁) on spirometry than those on Nintedanib. The six-minute walk test (6MWT) indicated greater improvement in the Nintedanib group (11.6 meters). Therapy response varied with ILD subtype.
CONCLUSIONS: This study shows that Nintedanib is effective in fibrotic ILDs, while corticosteroids benefit inflammatory types. The findings highlight the complexity of ILD management and the need for further research to optimize treatment strategies. This work lays a foundation for evidence-based, personalized ILD care.
Conference/Value in Health Info
2025-09, ISPOR Real-World Evidence Summit 2025, Tokyo, Japan
Value in Health Regional, Volume 49S (September 2025)
Code
RWD155
Topic Subcategory
Reproducibility & Replicability
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)